nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—Spinal Cord Injury—AIF1—systemic scleroderma	0.00349	0.209	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00171	0.102	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—SELP—systemic scleroderma	0.00152	0.0911	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—RHOB—systemic scleroderma	0.00142	0.085	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Azathioprine—systemic scleroderma	0.0012	0.00122	CcSEcCtD
Fosaprepitant—Rash—Mometasone—systemic scleroderma	0.0012	0.00122	CcSEcCtD
Fosaprepitant—Asthenia—Captopril—systemic scleroderma	0.0012	0.00122	CcSEcCtD
Fosaprepitant—Dermatitis—Mometasone—systemic scleroderma	0.0012	0.00122	CcSEcCtD
Fosaprepitant—Decreased appetite—Leflunomide—systemic scleroderma	0.0012	0.00122	CcSEcCtD
Fosaprepitant—Osteoarthritis—Methotrexate—systemic scleroderma	0.0012	0.00122	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00119	0.00121	CcSEcCtD
Fosaprepitant—Headache—Mometasone—systemic scleroderma	0.00119	0.00121	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00119	0.00121	CcSEcCtD
Fosaprepitant—Insomnia—Mycophenolic acid—systemic scleroderma	0.00119	0.00121	CcSEcCtD
Fosaprepitant—Fatigue—Leflunomide—systemic scleroderma	0.00119	0.00121	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Oedema—Lisinopril—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Pruritus—Captopril—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Pain—Leflunomide—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Constipation—Leflunomide—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Infection—Lisinopril—systemic scleroderma	0.00118	0.0012	CcSEcCtD
Fosaprepitant—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00117	0.0012	CcSEcCtD
Fosaprepitant—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00117	0.00119	CcSEcCtD
Fosaprepitant—Somnolence—Mycophenolic acid—systemic scleroderma	0.00117	0.00119	CcSEcCtD
Fosaprepitant—Shock—Lisinopril—systemic scleroderma	0.00116	0.00119	CcSEcCtD
Fosaprepitant—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00118	CcSEcCtD
Fosaprepitant—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00116	0.00118	CcSEcCtD
Fosaprepitant—Abdominal pain—Azathioprine—systemic scleroderma	0.00115	0.00117	CcSEcCtD
Fosaprepitant—Body temperature increased—Azathioprine—systemic scleroderma	0.00115	0.00117	CcSEcCtD
Fosaprepitant—Skin disorder—Lisinopril—systemic scleroderma	0.00115	0.00117	CcSEcCtD
Fosaprepitant—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00117	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00114	0.00116	CcSEcCtD
Fosaprepitant—Diarrhoea—Captopril—systemic scleroderma	0.00114	0.00116	CcSEcCtD
Fosaprepitant—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00114	0.00116	CcSEcCtD
Fosaprepitant—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00116	CcSEcCtD
Fosaprepitant—Feeling abnormal—Leflunomide—systemic scleroderma	0.00114	0.00116	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00113	0.00115	CcSEcCtD
Fosaprepitant—Fatigue—Mycophenolic acid—systemic scleroderma	0.00113	0.00115	CcSEcCtD
Fosaprepitant—Nausea—Mometasone—systemic scleroderma	0.00113	0.00115	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00113	0.00115	CcSEcCtD
Fosaprepitant—Constipation—Mycophenolic acid—systemic scleroderma	0.00112	0.00114	CcSEcCtD
Fosaprepitant—Pain—Mycophenolic acid—systemic scleroderma	0.00112	0.00114	CcSEcCtD
Fosaprepitant—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00114	CcSEcCtD
Fosaprepitant—Weight decreased—Prednisone—systemic scleroderma	0.00112	0.00114	CcSEcCtD
Fosaprepitant—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00114	CcSEcCtD
Fosaprepitant—Cough—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00113	CcSEcCtD
Fosaprepitant—Hypotension—Lisinopril—systemic scleroderma	0.00111	0.00113	CcSEcCtD
Fosaprepitant—Dizziness—Captopril—systemic scleroderma	0.00111	0.00112	CcSEcCtD
Fosaprepitant—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.0011	0.00112	CcSEcCtD
Fosaprepitant—Urticaria—Leflunomide—systemic scleroderma	0.00109	0.00111	CcSEcCtD
Fosaprepitant—Body temperature increased—Leflunomide—systemic scleroderma	0.00109	0.00111	CcSEcCtD
Fosaprepitant—Abdominal pain—Leflunomide—systemic scleroderma	0.00109	0.00111	CcSEcCtD
Fosaprepitant—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00108	0.0011	CcSEcCtD
Fosaprepitant—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00108	0.0011	CcSEcCtD
Fosaprepitant—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00108	0.0011	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.00108	0.0011	CcSEcCtD
Fosaprepitant—Hypersensitivity—Azathioprine—systemic scleroderma	0.00108	0.00109	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00107	0.00109	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00109	CcSEcCtD
Fosaprepitant—Insomnia—Lisinopril—systemic scleroderma	0.00107	0.00109	CcSEcCtD
Fosaprepitant—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00109	CcSEcCtD
Fosaprepitant—Vomiting—Captopril—systemic scleroderma	0.00106	0.00108	CcSEcCtD
Fosaprepitant—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00108	CcSEcCtD
Fosaprepitant—Dyspnoea—Lisinopril—systemic scleroderma	0.00106	0.00107	CcSEcCtD
Fosaprepitant—Rash—Captopril—systemic scleroderma	0.00105	0.00107	CcSEcCtD
Fosaprepitant—Dermatitis—Captopril—systemic scleroderma	0.00105	0.00107	CcSEcCtD
Fosaprepitant—Somnolence—Lisinopril—systemic scleroderma	0.00105	0.00107	CcSEcCtD
Fosaprepitant—Headache—Captopril—systemic scleroderma	0.00105	0.00107	CcSEcCtD
Fosaprepitant—Dyspepsia—Lisinopril—systemic scleroderma	0.00104	0.00106	CcSEcCtD
Fosaprepitant—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00104	0.00106	CcSEcCtD
Fosaprepitant—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00104	0.00106	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00106	CcSEcCtD
Fosaprepitant—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00106	CcSEcCtD
Fosaprepitant—Infection—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00105	CcSEcCtD
Fosaprepitant—Decreased appetite—Lisinopril—systemic scleroderma	0.00103	0.00105	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00102	0.00104	CcSEcCtD
Fosaprepitant—Fatigue—Lisinopril—systemic scleroderma	0.00102	0.00104	CcSEcCtD
Fosaprepitant—Shock—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00104	CcSEcCtD
Fosaprepitant—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00104	CcSEcCtD
Fosaprepitant—Hypersensitivity—Leflunomide—systemic scleroderma	0.00102	0.00103	CcSEcCtD
Fosaprepitant—Pain—Lisinopril—systemic scleroderma	0.00101	0.00103	CcSEcCtD
Fosaprepitant—Constipation—Lisinopril—systemic scleroderma	0.00101	0.00103	CcSEcCtD
Fosaprepitant—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00103	CcSEcCtD
Fosaprepitant—Bradycardia—Prednisone—systemic scleroderma	0.00101	0.00103	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.001	0.00102	CcSEcCtD
Fosaprepitant—Diarrhoea—Azathioprine—systemic scleroderma	0.000998	0.00102	CcSEcCtD
Fosaprepitant—Nausea—Captopril—systemic scleroderma	0.000993	0.00101	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000991	0.00101	CcSEcCtD
Fosaprepitant—Asthenia—Leflunomide—systemic scleroderma	0.000989	0.00101	CcSEcCtD
Fosaprepitant—Feeling abnormal—Lisinopril—systemic scleroderma	0.000976	0.000993	CcSEcCtD
Fosaprepitant—Pruritus—Leflunomide—systemic scleroderma	0.000975	0.000992	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Prednisone—systemic scleroderma	0.000973	0.00099	CcSEcCtD
Fosaprepitant—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000969	0.000986	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000968	0.000985	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—systemic scleroderma	0.000966	0.000983	CcSEcCtD
Fosaprepitant—Dizziness—Azathioprine—systemic scleroderma	0.000965	0.000982	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000943	0.00096	CcSEcCtD
Fosaprepitant—Asthenia—Mycophenolic acid—systemic scleroderma	0.000943	0.00096	CcSEcCtD
Fosaprepitant—Diarrhoea—Leflunomide—systemic scleroderma	0.000943	0.000959	CcSEcCtD
Fosaprepitant—Urticaria—Lisinopril—systemic scleroderma	0.000941	0.000957	CcSEcCtD
Fosaprepitant—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000938	0.000955	CcSEcCtD
Fosaprepitant—Body temperature increased—Lisinopril—systemic scleroderma	0.000936	0.000952	CcSEcCtD
Fosaprepitant—Abdominal pain—Lisinopril—systemic scleroderma	0.000936	0.000952	CcSEcCtD
Fosaprepitant—Pruritus—Mycophenolic acid—systemic scleroderma	0.00093	0.000946	CcSEcCtD
Fosaprepitant—Vomiting—Azathioprine—systemic scleroderma	0.000928	0.000944	CcSEcCtD
Fosaprepitant—Eye disorder—Prednisone—systemic scleroderma	0.000925	0.000941	CcSEcCtD
Fosaprepitant—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000925	0.000941	CcSEcCtD
Fosaprepitant—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000922	0.000938	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—systemic scleroderma	0.000921	0.000938	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—systemic scleroderma	0.000921	0.000938	CcSEcCtD
Fosaprepitant—Rash—Azathioprine—systemic scleroderma	0.00092	0.000936	CcSEcCtD
Fosaprepitant—Dermatitis—Azathioprine—systemic scleroderma	0.000919	0.000935	CcSEcCtD
Fosaprepitant—Flushing—Prednisone—systemic scleroderma	0.000919	0.000935	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000916	0.0549	CbGpPWpGaD
Fosaprepitant—Headache—Azathioprine—systemic scleroderma	0.000914	0.00093	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000914	0.00093	CcSEcCtD
Fosaprepitant—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000913	0.000929	CcSEcCtD
Fosaprepitant—Dizziness—Leflunomide—systemic scleroderma	0.000911	0.000927	CcSEcCtD
Fosaprepitant—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000902	0.000918	CcSEcCtD
Fosaprepitant—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000899	0.000915	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—systemic scleroderma	0.000898	0.000914	CcSEcCtD
Fosaprepitant—Angiopathy—Prednisone—systemic scleroderma	0.000898	0.000914	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—systemic scleroderma	0.000896	0.000911	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000896	0.000911	CcSEcCtD
Fosaprepitant—Immune system disorder—Prednisone—systemic scleroderma	0.000894	0.00091	CcSEcCtD
Fosaprepitant—Pain—Mycophenolate mofetil—systemic scleroderma	0.000887	0.000903	CcSEcCtD
Fosaprepitant—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000887	0.000903	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—systemic scleroderma	0.000879	0.000894	CcSEcCtD
Fosaprepitant—Vomiting—Leflunomide—systemic scleroderma	0.000876	0.000891	CcSEcCtD
Fosaprepitant—Hypersensitivity—Lisinopril—systemic scleroderma	0.000872	0.000888	CcSEcCtD
Fosaprepitant—Dizziness—Mycophenolic acid—systemic scleroderma	0.000869	0.000885	CcSEcCtD
Fosaprepitant—Rash—Leflunomide—systemic scleroderma	0.000869	0.000884	CcSEcCtD
Fosaprepitant—Dermatitis—Leflunomide—systemic scleroderma	0.000868	0.000883	CcSEcCtD
Fosaprepitant—Mental disorder—Prednisone—systemic scleroderma	0.000867	0.000882	CcSEcCtD
Fosaprepitant—Nausea—Azathioprine—systemic scleroderma	0.000867	0.000882	CcSEcCtD
Fosaprepitant—Headache—Leflunomide—systemic scleroderma	0.000863	0.000878	CcSEcCtD
Fosaprepitant—Erythema—Prednisone—systemic scleroderma	0.000862	0.000877	CcSEcCtD
Fosaprepitant—Malnutrition—Prednisone—systemic scleroderma	0.000862	0.000877	CcSEcCtD
Fosaprepitant—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000855	0.00087	CcSEcCtD
Fosaprepitant—Asthenia—Lisinopril—systemic scleroderma	0.000849	0.000864	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000848	0.000863	CcSEcCtD
Fosaprepitant—Pruritus—Lisinopril—systemic scleroderma	0.000838	0.000852	CcSEcCtD
Fosaprepitant—Vomiting—Mycophenolic acid—systemic scleroderma	0.000836	0.00085	CcSEcCtD
Fosaprepitant—Rash—Mycophenolic acid—systemic scleroderma	0.000829	0.000843	CcSEcCtD
Fosaprepitant—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000828	0.000843	CcSEcCtD
Fosaprepitant—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000824	0.000839	CcSEcCtD
Fosaprepitant—Headache—Mycophenolic acid—systemic scleroderma	0.000823	0.000838	CcSEcCtD
Fosaprepitant—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00082	0.000834	CcSEcCtD
Fosaprepitant—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00082	0.000834	CcSEcCtD
Fosaprepitant—Nausea—Leflunomide—systemic scleroderma	0.000818	0.000833	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000817	0.000831	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—systemic scleroderma	0.000811	0.000825	CcSEcCtD
Fosaprepitant—Diarrhoea—Lisinopril—systemic scleroderma	0.00081	0.000824	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Prednisone—systemic scleroderma	0.000799	0.000813	CcSEcCtD
Fosaprepitant—Anaemia—Prednisone—systemic scleroderma	0.000796	0.00081	CcSEcCtD
Fosaprepitant—Angioedema—Prednisone—systemic scleroderma	0.000787	0.000801	CcSEcCtD
Fosaprepitant—Dizziness—Lisinopril—systemic scleroderma	0.000783	0.000797	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—systemic scleroderma	0.000782	0.000796	CcSEcCtD
Fosaprepitant—Nausea—Mycophenolic acid—systemic scleroderma	0.000781	0.000794	CcSEcCtD
Fosaprepitant—Malaise—Prednisone—systemic scleroderma	0.000777	0.000791	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—systemic scleroderma	0.000773	0.000787	CcSEcCtD
Fosaprepitant—Syncope—Prednisone—systemic scleroderma	0.000773	0.000786	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—systemic scleroderma	0.000771	0.000785	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—systemic scleroderma	0.000768	0.000781	CcSEcCtD
Fosaprepitant—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000764	0.000778	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisone—systemic scleroderma	0.000757	0.000771	CcSEcCtD
Fosaprepitant—Vomiting—Lisinopril—systemic scleroderma	0.000753	0.000766	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—systemic scleroderma	0.00075	0.000764	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—systemic scleroderma	0.000747	0.00076	CcSEcCtD
Fosaprepitant—Rash—Lisinopril—systemic scleroderma	0.000747	0.00076	CcSEcCtD
Fosaprepitant—Dermatitis—Lisinopril—systemic scleroderma	0.000746	0.000759	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000745	0.000759	CcSEcCtD
Fosaprepitant—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000744	0.000757	CcSEcCtD
Fosaprepitant—Hypertension—Prednisone—systemic scleroderma	0.000744	0.000757	CcSEcCtD
Fosaprepitant—Headache—Lisinopril—systemic scleroderma	0.000742	0.000755	CcSEcCtD
Fosaprepitant—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000734	0.000747	CcSEcCtD
Fosaprepitant—Anxiety—Prednisone—systemic scleroderma	0.000731	0.000744	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000728	0.000741	CcSEcCtD
Fosaprepitant—Discomfort—Prednisone—systemic scleroderma	0.000725	0.000737	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—systemic scleroderma	0.000725	0.000737	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1A—systemic scleroderma	0.000721	0.0432	CbGpPWpGaD
Fosaprepitant—Erythema—Methotrexate—systemic scleroderma	0.00072	0.000733	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—systemic scleroderma	0.00072	0.000733	CcSEcCtD
Fosaprepitant—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00071	0.000722	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—systemic scleroderma	0.000705	0.000718	CcSEcCtD
Fosaprepitant—Nausea—Lisinopril—systemic scleroderma	0.000703	0.000716	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisone—systemic scleroderma	0.000703	0.000716	CcSEcCtD
Fosaprepitant—Oedema—Prednisone—systemic scleroderma	0.000703	0.000716	CcSEcCtD
Fosaprepitant—Infection—Prednisone—systemic scleroderma	0.000699	0.000711	CcSEcCtD
Fosaprepitant—Shock—Prednisone—systemic scleroderma	0.000692	0.000704	CcSEcCtD
Fosaprepitant—Nervous system disorder—Prednisone—systemic scleroderma	0.00069	0.000702	CcSEcCtD
Fosaprepitant—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000686	0.000698	CcSEcCtD
Fosaprepitant—Skin disorder—Prednisone—systemic scleroderma	0.000683	0.000695	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisone—systemic scleroderma	0.00068	0.000692	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000668	0.00068	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—systemic scleroderma	0.000666	0.000677	CcSEcCtD
Fosaprepitant—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00066	0.000671	CcSEcCtD
Fosaprepitant—Rash—Mycophenolate mofetil—systemic scleroderma	0.000654	0.000666	CcSEcCtD
Fosaprepitant—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000653	0.000665	CcSEcCtD
Fosaprepitant—Headache—Mycophenolate mofetil—systemic scleroderma	0.00065	0.000661	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—systemic scleroderma	0.000649	0.000661	CcSEcCtD
Fosaprepitant—Insomnia—Prednisone—systemic scleroderma	0.000636	0.000647	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—systemic scleroderma	0.000628	0.000639	CcSEcCtD
Fosaprepitant—Dyspepsia—Prednisone—systemic scleroderma	0.000619	0.00063	CcSEcCtD
Fosaprepitant—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000627	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—systemic scleroderma	0.000613	0.000624	CcSEcCtD
Fosaprepitant—Decreased appetite—Prednisone—systemic scleroderma	0.000611	0.000622	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000609	0.000619	CcSEcCtD
Fosaprepitant—Fatigue—Prednisone—systemic scleroderma	0.000606	0.000617	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—systemic scleroderma	0.000606	0.000616	CcSEcCtD
Fosaprepitant—Constipation—Prednisone—systemic scleroderma	0.000601	0.000612	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000588	0.000598	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—systemic scleroderma	0.000584	0.000594	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisone—systemic scleroderma	0.000579	0.00059	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000577	0.0345	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Methotrexate—systemic scleroderma	0.000576	0.000586	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000575	0.000585	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—systemic scleroderma	0.000571	0.000581	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000568	0.000578	CcSEcCtD
Fosaprepitant—Urticaria—Prednisone—systemic scleroderma	0.000559	0.000568	CcSEcCtD
Fosaprepitant—Abdominal pain—Prednisone—systemic scleroderma	0.000556	0.000566	CcSEcCtD
Fosaprepitant—Body temperature increased—Prednisone—systemic scleroderma	0.000556	0.000566	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—systemic scleroderma	0.000549	0.000559	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—systemic scleroderma	0.000532	0.000541	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—systemic scleroderma	0.000524	0.000533	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—systemic scleroderma	0.000522	0.000532	CcSEcCtD
Fosaprepitant—Hypersensitivity—Prednisone—systemic scleroderma	0.000518	0.000527	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—systemic scleroderma	0.000517	0.000526	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—systemic scleroderma	0.000511	0.00052	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000507	0.000516	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—systemic scleroderma	0.000507	0.000516	CcSEcCtD
Fosaprepitant—Asthenia—Prednisone—systemic scleroderma	0.000505	0.000513	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—systemic scleroderma	0.000503	0.000511	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000502	0.03	CbGpPWpGaD
Fosaprepitant—Pruritus—Prednisone—systemic scleroderma	0.000498	0.000506	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CCL2—systemic scleroderma	0.000496	0.0297	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000495	0.0297	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Methotrexate—systemic scleroderma	0.000484	0.000493	CcSEcCtD
Fosaprepitant—Diarrhoea—Prednisone—systemic scleroderma	0.000481	0.00049	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000481	0.000489	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—systemic scleroderma	0.000467	0.000475	CcSEcCtD
Fosaprepitant—Dizziness—Prednisone—systemic scleroderma	0.000465	0.000473	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—systemic scleroderma	0.000465	0.000473	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—systemic scleroderma	0.000465	0.000473	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000449	0.0269	CbGpPWpGaD
Fosaprepitant—Vomiting—Prednisone—systemic scleroderma	0.000447	0.000455	CcSEcCtD
Fosaprepitant—Rash—Prednisone—systemic scleroderma	0.000443	0.000451	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisone—systemic scleroderma	0.000443	0.000451	CcSEcCtD
Fosaprepitant—Headache—Prednisone—systemic scleroderma	0.000441	0.000448	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—systemic scleroderma	0.000433	0.000441	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—systemic scleroderma	0.000422	0.000429	CcSEcCtD
Fosaprepitant—Nausea—Prednisone—systemic scleroderma	0.000418	0.000425	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—systemic scleroderma	0.000416	0.000423	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—systemic scleroderma	0.000402	0.000409	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—systemic scleroderma	0.000389	0.000395	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1B—systemic scleroderma	0.000376	0.0225	CbGpPWpGaD
Fosaprepitant—Vomiting—Methotrexate—systemic scleroderma	0.000374	0.00038	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—systemic scleroderma	0.000371	0.000377	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—systemic scleroderma	0.00037	0.000377	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—systemic scleroderma	0.000368	0.000375	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—systemic scleroderma	0.000354	0.0212	CbGpPWpGaD
Fosaprepitant—Nausea—Methotrexate—systemic scleroderma	0.000349	0.000355	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000339	0.0203	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000332	0.0199	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000301	0.018	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000292	0.0175	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.00028	0.0168	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RHOB—systemic scleroderma	0.000254	0.0152	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDN1—systemic scleroderma	0.000253	0.0151	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000227	0.0136	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SMAD7—systemic scleroderma	0.000194	0.0116	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCL2—systemic scleroderma	0.000173	0.0104	CbGpPWpGaD
Fosaprepitant—TACR1—connective tissue—systemic scleroderma	0.000164	0.309	CbGeAlD
Fosaprepitant—TACR1—Signaling Pathways—RHOB—systemic scleroderma	0.00015	0.00899	CbGpPWpGaD
Fosaprepitant—TACR1—smooth muscle tissue—systemic scleroderma	0.00015	0.282	CbGeAlD
Fosaprepitant—TACR1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000143	0.00856	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HSPG2—systemic scleroderma	0.000142	0.00848	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CSK—systemic scleroderma	0.000137	0.00819	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EDN1—systemic scleroderma	0.00013	0.00777	CbGpPWpGaD
Fosaprepitant—TACR1—digestive system—systemic scleroderma	0.000118	0.223	CbGeAlD
Fosaprepitant—TACR1—lung—systemic scleroderma	9.87e-05	0.186	CbGeAlD
Fosaprepitant—TACR1—Signaling by GPCR—CCL2—systemic scleroderma	8.88e-05	0.00531	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDN1—systemic scleroderma	7.67e-05	0.00459	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL2—systemic scleroderma	5.24e-05	0.00314	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—systemic scleroderma	4.67e-05	0.0028	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—systemic scleroderma	3.75e-05	0.00224	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—systemic scleroderma	3.09e-05	0.00185	CbGpPWpGaD
